| Project/Area Number |
23659281
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
UMEMURA Kazuo 浜松医科大学, 医学部, 教授 (40232912)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | ADP (P2Y12) 受容体 / 移植後動脈硬化 / 平滑筋様細胞 / 遊走 / 分化 / P2Y12受容体 / 遊走能 / 血管平滑筋細胞 / P2Y12 |
|---|
| Research Abstract |
The role of ADP (P2Y12) receptor on smooth muscle like cells (SMLCs) in the development of transplant arteriosclerosis (TA) was examined. A stable ADP analog, 2-methylthio-ADP-induced cell migration was significantly decreased in P2Y 12-deficient-SMLCs. In addition, the migration was significantly decreased by the pretreatment with wortmannin (phosphoinositide 3-kinase [PI3K] inhibitor) or PD98059 (extracellular signal-regulated kinase [ERK] inhibitor). However, the differentiation of bone marrow-derived cells into SMLCs was not associated with P2Y12 receptors. Thus, the migration of SMLCs mediated by P2Y12 receptors may play an important role in the development of TA, via PI3K-Akt and ERK signaling pathways.
|
